Platform Technology

About Stipple Bio

Stipple Bio is a San Diego-based biotech founded in 2021, focused on developing a proprietary platform for high-resolution cellular profiling and target discovery. The company's mission centers on unlocking biological insights at the epitope level to drive the identification of novel therapeutic targets and biomarkers. While still in its early stages, Stipple Bio represents an emerging player in the rapidly evolving field of single-cell and spatial biology technologies.

About Stabilux Biosciences

StabiLux Biosciences is an early-stage biotech firm pioneering a nanoparticle-based dye platform to dramatically improve biomarker detection sensitivity. Founded in 2020, the company leverages proprietary boron nitride nanoparticles to create 'StabiLux Bright Technology,' which can be conjugated with existing dyes and biomolecules like antibodies and RNA. This platform targets critical unmet needs in early cancer detection, immunology research, and therapeutic development by enabling researchers to 'detect the undetectable.' The company appears to be in a pre-revenue, platform-validation stage, building on over a decade of academic research from Michigan Technological University.

Therapeutic Areas